Tirzepatide: uses, dosing, side effects & brands

MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker.

The FDA classifies tirzepatide as a glp-1 receptor agonist. GLP-1 receptor agonists mimic the gut hormone GLP-1: they prompt the pancreas to release insulin when blood sugar is high, curb the release of glucagon, and slow stomach emptying, which lowers blood sugar and reduces appetite. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The elimination half-life of tirzepatide is about 5 days (roughly 120 hours) — that is how long the body takes to clear half of a dose. This is the elimination half-life of tirzepatide itself; the long duration is what allows once-weekly injection, and the same molecule and half-life apply to both Mounjaro and Zepbound. The FDA label reports no active metabolite with a longer half-life. Individual values can vary somewhat between people. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run tirzepatide against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 6 tirzepatide-containing products in the U.S.: Mounjaro, Mounjaro (Autoinjector), Mounjaro Kwikpen, Zepbound, Zepbound (Autoinjector) and Zepbound Kwikpen. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, tirzepatide is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

We do not currently list a generic-labelled tirzepatide product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

The FDA's Enforcement database lists at least 5 recall records whose product description mentions tirzepatide. The most recent: Tirzepatide Inj (Feb 26, 2026). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, and decreased appetite, along with injection-site reactions and fatigue. Nausea and diarrhea are the most frequent. These effects are dose-related — they tend to be worst right after a dose increase and for most people ease over the following days to weeks as the body adjusts. Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist, and this slowed-stomach-emptying effect is what drives the digestive symptoms.

Get urgent medical care for these. MedlinePlus says to "stop taking tirzepatide and call your doctor immediately" for "stomach pain that will not go away (and may radiate to the back) with or without vomiting" — a possible sign of pancreatitis. Also call immediately for a possible severe allergic reaction: "swelling of the face, throat, or around the mouth or eyes; hives; rash; itching; trouble swallowing or breathing; dizziness; or a rapid heartbeat." Other serious risks include gallbladder problems (cholelithiasis/cholecystitis — upper-right belly pain, fever, yellowing of the skin or eyes), and acute kidney injury caused by dehydration when nausea, vomiting, or diarrhea are severe — so staying hydrated matters. Low blood sugar (hypoglycemia) is a serious risk mainly if you also take insulin or a sulfonylurea. This is not a complete list.

Yes. Tirzepatide carries the FDA's most serious ("boxed") warning for thyroid C-cell tumors. It caused thyroid tumors, including medullary thyroid carcinoma (MTC), in rodent studies; it is not known whether it causes these tumors in humans. Because of this, MedlinePlus advises telling your doctor "if you or anyone in your family has or ever had thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)" — if so, "your doctor will probably tell you not to use tirzepatide" (it is contraindicated). Report any lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. Note also that rapid improvement in blood sugar can temporarily worsen diabetic retinopathy in people who already have it, so keep up with eye exams.

Digestive side effects usually begin within the first days of starting and are most noticeable in the week or two after each dose increase (the dose is stepped up gradually — starting at 2.5 mg weekly — specifically to limit this). For most people the nausea and other GI symptoms fade over several weeks as the body adjusts. Eating smaller, lower-fat meals and stopping when full can help. If symptoms are severe, persistent, or you can't keep fluids down, contact your prescriber rather than pushing through — do not stop or change the dose on your own without talking to your doctor first.